Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2021 Conference Call
November 09, 2020 08:30 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference...
Medexus Announces Engagement of Westmount Capital and Equity Incentive Grants to Insiders
October 30, 2020 12:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has...
Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy
September 25, 2020 08:30 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced the appointment of Michael Pine as Senior Vice...
Medexus Engages Adelaide Capital for Investor Relations Services and Reports Annual Meeting Results
September 18, 2020 10:38 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) is pleased to announce that it has entered...
Medexus Reports Health Canada Approval of Gleolan® (5-ALA) for Use in Guided Surgical Resection of High-Grade Gliomas
September 10, 2020 09:20 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF) today announces that on September 9, 2020,...
Medexus Announces Move to a Virtual Meeting for 2020 AGM and Equity Incentive Grants
August 24, 2020 19:57 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that due to public health...
Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec’s RAMQ List of Medications (Basic Plan and Institutions)
August 24, 2020 08:00 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF) is pleased to announce that Triamcinolone Hexacetonide Injectable...
Medexus Announces New U.S. Ticker “MEDXF” on the OTCQX
August 21, 2020 11:36 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF; PDDPF) today announces that it has begun trading on the OTCQX® Best...
Medexus Pharmaceuticals Reports Record Revenue of $27.5 Million and $5.0 Million of Adjusted EBITDA* for the First Quarter of Fiscal 2021
August 11, 2020 17:19 ET
|
Medexus Pharmaceuticals Inc
Strong organic growth across all key product lines, including recently acquired IXINITY® Generated $4.1 million of cash flow from operations Management to host conference call at 8:00 AM ET on...
Medexus Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12th
August 11, 2020 08:30 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that it will be presenting at the Canaccord Genuity...